Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
acute kidney injury
allergy
immune checkpoint inhibitors
immunotherapy
nephrology
nephrotoxicity
pharmacovigilance
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
01
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) foster anti-cancer immune responses. Their efficacy comes at the cost of immune-related adverse events (IRAEs). The latter affects various organs, including kidneys, mostly as acute tubulointerstitial nephritis, the pathophysiology of which remains unclear. We conducted a multicentre case-control study to compare the characteristics of patients with renal IRAEs (ICI-AKI) with those of patients diagnosed with other IRAEs. We queried the French pharmacovigilance database for all adverse events involving ICIs. Reports were classified as ICI-AKI or extrarenal IRAE. For each ICI-AKI report, four reports of extrarenal IRAEs were randomly included (control group, 4:1 ratio). Variables showing an association with a P < 0.05 were included as covariates in a multivariate analysis. Therefore, 167 ICI-AKI reports were compared with 668 extrarenal IRAEs. At least one concomitant extrarenal IRAE was mentioned in 44.3% of ICI-AKI reports. Patients with ICI-AKI were significantly older than patients with extrarenal IRAEs (69.1 versus 64.6 years; P = 0.0135), and chronic kidney disease was significantly more prevalent (12.0% versus 3.3%; P = 0.0125). Patients with ICI-AKI were significantly more likely to be treated with fluindione [adjusted odds ratio (OR) 6.53, 95% confidence interval (95% CI) 2.21-19.31; P = 0.0007], a non-steroidal anti-inflammatory drug (NSAID, OR 3.18, 95% CI 1.07-9.4; P = 0.0368) or a proton-pump inhibitor (PPI, OR 2.18, 95% CI 1.42-3.34; P = 0.0004). This study is limited by a lack of data, preventing confirmation of numerous reports therefore not included in the analysis. We are unable to draw definite pathophysiological conclusions from our data. Nonetheless, we suggest that ICIs may be a 'second-hit' that precipitates acute kidney injury caused by another concomitant drug (fluindione, NSAID or PPI).
Sections du résumé
Background
UNASSIGNED
Immune checkpoint inhibitors (ICIs) foster anti-cancer immune responses. Their efficacy comes at the cost of immune-related adverse events (IRAEs). The latter affects various organs, including kidneys, mostly as acute tubulointerstitial nephritis, the pathophysiology of which remains unclear. We conducted a multicentre case-control study to compare the characteristics of patients with renal IRAEs (ICI-AKI) with those of patients diagnosed with other IRAEs.
Methods
UNASSIGNED
We queried the French pharmacovigilance database for all adverse events involving ICIs. Reports were classified as ICI-AKI or extrarenal IRAE. For each ICI-AKI report, four reports of extrarenal IRAEs were randomly included (control group, 4:1 ratio). Variables showing an association with a P < 0.05 were included as covariates in a multivariate analysis.
Results
UNASSIGNED
Therefore, 167 ICI-AKI reports were compared with 668 extrarenal IRAEs. At least one concomitant extrarenal IRAE was mentioned in 44.3% of ICI-AKI reports. Patients with ICI-AKI were significantly older than patients with extrarenal IRAEs (69.1 versus 64.6 years; P = 0.0135), and chronic kidney disease was significantly more prevalent (12.0% versus 3.3%; P = 0.0125). Patients with ICI-AKI were significantly more likely to be treated with fluindione [adjusted odds ratio (OR) 6.53, 95% confidence interval (95% CI) 2.21-19.31; P = 0.0007], a non-steroidal anti-inflammatory drug (NSAID, OR 3.18, 95% CI 1.07-9.4; P = 0.0368) or a proton-pump inhibitor (PPI, OR 2.18, 95% CI 1.42-3.34; P = 0.0004).
Conclusion
UNASSIGNED
This study is limited by a lack of data, preventing confirmation of numerous reports therefore not included in the analysis. We are unable to draw definite pathophysiological conclusions from our data. Nonetheless, we suggest that ICIs may be a 'second-hit' that precipitates acute kidney injury caused by another concomitant drug (fluindione, NSAID or PPI).
Identifiants
pubmed: 36158153
doi: 10.1093/ckj/sfac109
pii: sfac109
pmc: PMC9494514
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1881-1887Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Clin Kidney J. 2019 Feb;12(1):81-88
pubmed: 30746132
Cancer Immunol Immunother. 2021 Nov;70(11):3357-3364
pubmed: 34155532
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
Front Oncol. 2012 Apr 02;2:28
pubmed: 22649783
Am J Nephrol. 2017;45(2):160-169
pubmed: 28076863
Clin Kidney J. 2016 Jun;9(3):411-7
pubmed: 27274826
Kidney Int. 2020 Jan;97(1):62-74
pubmed: 31685311
Clin Kidney J. 2020 Feb 10;14(5):1364-1370
pubmed: 34221369
Clin Kidney J. 2020 May 04;14(3):884-890
pubmed: 33777371
Nephrol Dial Transplant. 2017 Jun 1;32(6):936-942
pubmed: 28025384
Presse Med. 2014 Nov;43(11):e369-76
pubmed: 25218248
Cancers (Basel). 2019 Nov 15;11(11):
pubmed: 31731818
Clin Kidney J. 2019 Jun 21;14(1):418-420
pubmed: 33564446
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Nephrol Ther. 2009 Jul;5(4):292-8
pubmed: 19357010
Clin Kidney J. 2021 Mar 10;14(5):1301-1306
pubmed: 33970161
J Natl Cancer Inst. 2021 Oct 1;113(10):1396-1404
pubmed: 33705549
Nephrol Dial Transplant. 2019 Jan 1;34(1):108-117
pubmed: 29762725
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34625513
Am J Kidney Dis. 2016 Aug;68(2):287-291
pubmed: 27113507
Front Oncol. 2021 May 13;11:619385
pubmed: 34055598
Invest New Drugs. 2014 Aug;32(4):769-73
pubmed: 24687600
BMC Nephrol. 2020 Sep 7;21(1):391
pubmed: 32894101
Kidney360. 2020 Jan 14;1(2):130-140
pubmed: 35372904
Clin Kidney J. 2021 Dec 24;15(5):873-884
pubmed: 35498895
J Am Soc Nephrol. 2020 Feb;31(2):435-446
pubmed: 31896554
Kidney Int. 2016 Sep;90(3):638-47
pubmed: 27282937
Drug Saf. 2019 Feb;42(2):281-294
pubmed: 30649742
Cancer Lett. 2019 Dec 1;466:35-38
pubmed: 31541696
J Am Soc Nephrol. 2018 Aug;29(8):2039-2052
pubmed: 29959196
Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9
pubmed: 16276663